AOA Dx Inc (YCS21) Revenue and Competitors

Boston, MA USA

Location

#2734

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • AOA Dx Inc (YCS21)'s estimated annual revenue is currently $5.7M per year.(i)
  • AOA Dx Inc (YCS21)'s estimated revenue per employee is $155,000

Employee Data

  • AOA Dx Inc (YCS21) has 37 Employees.(i)
  • AOA Dx Inc (YCS21) grew their employee count by 76% last year.

AOA Dx Inc (YCS21)'s People

NameTitleEmail/Phone
1
CEO & Co-FounderReveal Email/Phone
2
Head Immunoassay R&DReveal Email/Phone
3
Head Immunoassay R&DReveal Email/Phone
4
VP R&DReveal Email/Phone
5
VP Platform DevelopmentReveal Email/Phone
6
Chief Development Officer and Co-founderReveal Email/Phone
7
Director Clinical OperationsReveal Email/Phone
8
Director Business OperationsReveal Email/Phone
9
Laboratory TechnicianReveal Email/Phone
10
Clinical Trial AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is AOA Dx Inc (YCS21)?

AOA is a team of entrepreneurs and experts that bring innovative, impactful and cost-effective medical technologies from research and development into the hands of providers and patients. The co-founders have worked together for over 8 years, combining 30 years of experience bringing products from concept to commercialization across global markets. AOA's mission is to bring to market the first accurate early stage ovarian cancer diagnostic test that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. www.aoadx.com

keywords:N/A

N/A

Total Funding

37

Number of Employees

$5.7M

Revenue (est)

76%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.1M370%$8.1M
#2
$6.1M37-23%N/A
#3
$9.6M3728%N/A
#4
$6.2M37-7%N/A
#5
$4.3M37N/AN/A